SQLite Web: event_store.db

Update row 953 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:cfb2ac97dd1a1fae","evidence_event_ids":["evt_f89061a86207"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt","company":"Vericel Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt","article_chars":2199,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_86cdffbca1f5357d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:34:50.787178+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt","source_event_id":"evt_f89061a86207","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"5a41e78f7feb6614","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-06","2026-04-02","2025-05-30","2019-08-20","2015","2028-08-20"],"entities":[{"asset_class":"equity","name":"Vericel Corp","relevance":"high","symbol":"VCEL","type":"issuer"},{"asset_class":"equity","name":"Jonathan Mark Hopper","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"equity","name":"Hopper Jonathan Mark","relevance":"medium","symbol":"","type":"reporting_person_alias"}],"event_type":"listing","information_gaps":["What specific number of shares were sold and at what prices are not clearly extracted from the provided text (the cleaned text includes some numeric fragments but does not present a clear, complete transaction table).","The signal is labeled as a 'delta' but no prior known state is included in the provided text, so 'what changed vs prior' cannot be determined from this input alone.","No explicit statement of net proceeds or total transaction value is clearly extractable from the provided text."],"key_facts":["SEC filing: Form 4 (Conformed submission type: 4) for Vericel Corp.","Filing accession number: 0001140361-26-013334; filed as of date: 2026-04-06; conformed period of report: 2026-04-02.","Reporting person: Jonathan Mark Hopper; identified as Chief Medical Officer.","The filing states the sales reported were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025.","The filing states the options represent the right to purchase 135,000 shares.","The filing states these options became exercisable on August 20, 2019, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.","The filing includes language that shares acquired pursuant to the Issuer\u2019s 2015 Employee Stock Purchase Plan were exempt under Rule 16b-3(d) and Rule 16b-3(c)."],"numeric_claims":[{"label":"options_right_to_purchase_shares","value":"135,000"},{"label":"rule_10b5_1_adoption_date","value":"2025-05-30"},{"label":"options_exercisable_date","value":"2019-08-20"},{"label":"vesting_initial_percent","value":"25%"},{"label":"vesting_remaining_percent","value":"75%"},{"label":"vesting_remaining_duration","value":"3 years"},{"label":"filing_date_as_of","value":"2026-04-06"},{"label":"period_of_report","value":"2026-04-02"}],"primary_claim":"On 2026-04-06, Vericel Corp filed Form 4 reporting that Chief Medical Officer Jonathan Mark Hopper\u2019s reported sales were effected via an automatic sale under a Rule 10b5-1 trading plan adopted May 30, 2025, and the options involved represent the right to purchase 135,000 shares.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Vericel Corp (VCEL) filed a Form 4 on 2026-04-06 reporting transactions by reporting person Jonathan Mark Hopper (Chief Medical Officer). The filing indicates option-related activity tied to a Rule 10b5-1 automatic sale plan and describes vesting/exercise terms for options covering 135,000 shares.","topics":["SEC Form 4","insider transaction","Rule 10b5-1","employee stock purchase plan","stock options","vesting schedule"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Vericel Corp \u00b7 Filed 20260406","ticker":"VCEL","tickers":["VCEL"],"title":"VCEL filed 4","url":"https://www.sec.gov/Archives/edgar/data/887359/0001140361-26-013334.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel